For more than 90 years, Novo Nordisk has led the advancement of diabetes care. Headquartered in Denmark, the company ranks #8 with a brand value of USD $10.206 billion. In addition to focusing on metabolic diseases, Novo Nordisk targets hemophilia, growth hormone therapy, and hormone replacement therapy.
Novo Nordisk’s brand performance is a true reflection of the company’s mission to prevent, treat, and cure diabetes, and to improve the lives of those with chronic conditions, as well as its standing as a category leader in diabetes care. As Novo Nordisk continues to deliver on this heritage, the corporate brand performs well above the industry average in its ability to impact healthcare professional (HCP) decision-making.
HCPs recognize Novo Nordisk for its dedication to improving the lives of patients living with chronic diseases. HCPs acknowledge that the company consistently delivers healthcare solutions that exceed expectations, while offering supportive services along with its products. Novo Nordisk is also viewed as a prominent thought leader and go-to source of information on metabolic diseases.